ACXP ▼ -0.7% - Acurx Pharmaceuticals, Inc. $ACXP ACXP - Acurx Announces Presentation of a Scientific Poster at the Premier International C. difficile Symposium (ICDS) Demonstrating Superior In Vitro Kill Kinetics of Ibezapolstat vs. Vancomycin and Fidaxomicin (Standards of Care) in Clostridioides difficile and Vancomycin-Resistant Enterococcus Co-Cultures Acurx Pharmaceuticals fell 0.7% today despite announcing positive in vitro data showing its investigational drug ibezapolstat demonstrated superior kill kinetics against *Clostridioides difficile* and vancomycin-resistant enterococcus compared to current standard-of-care treatments in a poster presentation at the International C. difficile Symposium. The modest decline suggests the market may have already priced in expectations for the preclinical findings, or investors are awaiting clinical trial data in patients rather than laboratory results. 14-SEP-2026 08:04 AM ET